Open AccessAbstract CT136: Phase I study with rapamycin combined with irinotecan, the SFCE RAPIRI I trial, a new way to target tumor hypoxia in pediatric refractory cancers
Author(s) -
Sarah Jannier,
Véronique Kemmel,
Consuelo Sebastia,
Agathe Chammas,
Amélia-Naomi Sabo,
Erwan Pencreach,
Françoise Farace,
Benoît Lhermitte,
Birgit Geoerger,
Isabelle Aerts,
D. Frappaz,
Pierre Leblond,
Nicolas André,
Yves Pérel,
Nadège Corradini,
Anne Isabelle Bertozzi,
Florence Vincent,
Natacha EntzWerlé
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct136
Subject(s) - irinotecan , medicine , pharmacokinetics , pharmacodynamics , clinical endpoint , refractory (planetary science) , pharmacology , gastroenterology , clinical trial , cancer , colorectal cancer , biology , astrobiology